Yellowstone Private Investor Evening- 25 February 2026

Companies presenting: Ilika PLC, Poolbeg Pharma PLC, Kelso PLC First Tin PLC
Date: 25/02/2026
Time: 5:30pm
Location: London EC1

Event: Yellowstone Advisory Private Investor Evening
Description: Ilika, Poolbeg Pharma, Kelso & First Tin present their investment case followed by Q&A and the opportunity for informal discussions with management over drinks and canapés.
Ilika PLC
Speaker 1: Graeme Purdy, CEO
Bio: Graeme is the founding CEO of Ilika and a pioneer in the field of solid state batteries. Building from a program of high throughput materials development collaborations with Toyota on solid state electrolytes in the late 2000s, Ilika has progressed to developing two solid state battery product lines, both demonstrated on production-intent equipment: miniature Stereax batteries for med tech (now licensed to Cirtec Medical for manufacture) and large format Goliath batteries for electric vehicles and consumer appliances. Graeme is a Fellow of the Institution of Chemical Engineers in the UK and has an MBA from INSEAD business school in France.
Speaker 2: Jason Stewart, CFO
Bio: Jason is a senior Finance Director and Executive with significant commercial experience in the manufacturing sector. Most recently, Jason was the Interim CFO at Sunseeker International ltd where he successfully managed the company through the COVID-19 crisis, refinancing the business, managing costs and re-establishing production subsequent to the lockdown. A qualified accountant and Fellow of the Chartered Institute of Management Accountants (CIMA), Jason joined has been with Ilika since 2023 and prior to that fulfilling a number of senior roles at Sunseeker which he joined in 2010. Before joining Sunseeker, he spent five years with B&Q Ltd in various finance roles after he completed his professional training with Kerry Foods Ltd. He brings with him a wealth of knowledge across financial functions, with particular expertise in project appraisals, performance management and business development.
Company Description: Ilika is a global expert in the development of solid-state battery technology for electric vehicles, medical devices and consumer appliances. The Company’s pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products. The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries are designed for EV cars and cordless appliances. Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties. Stereax is licensed to US-headquartered medical device manufacturer Cirtec Medical.
Poolbeg Pharma PLC
Speaker: Jeremy Skillington, CEO
Bio: Jeremy Skillington, PhD began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech he was responsible for executing over 40 licensing, investment and collaboration transactions. Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German life science investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH. Jeremy joined Inflazome Ltd on its founding in 2016 and as VP of Business Development was instrumental in their acquisition by Roche in September 2020 for €380m upfront and significant downstream milestones for their portfolio of NLRP3 inflammasome inhibitors. He has been CEO of publicly listed Poolbeg Pharma Plc since June 2021.
Company Description: Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Kelso PLC
Speaker: John Goold, CEO
Bio: John qualified as a chartered accountant in London with Touche Ross in 1996 before a 25 year career in the City raising growth capital and advising small and mid cap companies. John initially started in corporate finance before moving into equity sales and corporate broking where he spent most of his career. During his career, John has helped raise over £5.0 billion for his clients much of which was while he was Chief Executive of Zeus from 2012 to 2021.
Company Description: Kelso is a listed activist investor on the main market with 5 material investments in UK small mid cap. Kelso seeks to help companies and their shareholders make positive change to improve shareholder value. Kelso is run by three market professionals John Goold, Jamie Brooke and Mark Kirkland with 100 City years of experience between them in broking, fund management and corporate finance. Kelso is the largest investor in Selkirk Plc which is a newly listed cash shell on the AIM market and single company acquisition vehicle in the consumer and technology sector backed by Sir Terry Leahy.
First Tin PLC
Speaker: Bill Scotting, CEO
Bio: Bill is an internationally experienced CEO, Director, senior executive and consultant with over 35 years’ experience in globally leading companies, primarily related to metals and mining. Previous roles include Head of Corporate Development at copper producer, Aurubis; CEO of zinc producer, Nyrstar; CEO of ArcelorMittal’s Mining division; Head of Strategy and Head of Performance Enhancement at ArcelorMittal; Consultant at McKinsey & Company and CRU International; Metallurgist at BHP.
Company Description: First Tin PLC is an ethical, reliable, and sustainable tin production company led by a team of renowned tin specialists. The Company is focused on becoming a tin supplier in conflict-free, low political risk jurisdictions through the rapid development of high value, low capex tin assets in Germany and Australia, which have been de-risked significantly, with extensive work undertaken to date. Tin is a critical metal, vital in any plan to decarbonise and electrify the world, yet Europe and North America have very little supply. Rising demand, together with shortages, is expected to lead tin to experience sustained deficit markets for the foreseeable future. First Tin’s goal is to use best-in-class environmental standards to bring two tin mines into production in three years, providing provenance of supply to support the current global clean energy and technological revolution.

Click here to register.